NEW REIMAGINED IDENTITY LIFESCIENCES AUSTRALIA REPOSITIONS FOR SECTOR Commences new initiatives in Company Directors training, Standards push and support for Early Career Stage workforce
With
Dr Tim Boyle PhD ChMPP,
Chief Executive Officer
LifeSciences Australia (formerly called ARCS Australia)
SEGMENT
Filmed in Sydney | June 2026
In June 2026, ARCS Australia formally became LifeSciences Australia — a name chosen to reflect the role the organisation plays across Australia’s life sciences sector.
Over more than 40 years, ARCS has grown well beyond its origins as a training and education body for regulatory and clinical specialists. Today, the organisation supports professionals across the entire life sciences sector — from early research through regulation, development and commercialisation — through an expanding range of programs and initiatives.
Following extensive member and stakeholder consultation throughout 2025 the name change was decided aiming to be a clearer, more inclusive identity reflecting the full breadth of Australia’s life sciences workforce and its role as the sector’s professional peak body.
Australian Health Journal was invited to the 2026 ARCS Conference in Sydney and met with Dr Tim Boyle Chief Executive Officer, LifeSciences Australia.
Source: Adapted from the ARCS Australia website
-
Psychiatrists to discuss connectedness at RANZCP 2023 Congress
Next week, at the Perth Convention and Exhibition Centre, The Royal Australian and New Zealand College of Psychiatrists (RANZCP) meet for the RANZCP 2023 Congress on the theme of “New Horizons: Connected Futures”
Australian Health Journal spoke to current President-Elect Dr Elizabeth Moore and soon to be President, RANZCP about the Congress, as well as the recent Federal Budget announcements around mental health funding.
-
Outstanding Achievement
George FaithfullGeorge has been in the medical device industry in a variety of roles for over 35 years including Sales, Marketing, Business Development, General Management, R&D, Clinical, Regulatory and Government Affairs. He has worked for Stryker in Australia, USA and across Asia.
-
Pathology technology at a crossroads
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
– Pathology Technology Australia’s key priorities in the coming years
– Current local capability in pathology technology compared to other countries
– How the health system supports change and adoption of pathology technology
– How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
– Observations in the Strengthening Medicare Taskforce ReportIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
